Newsletter | March 30, 2020

03.30.20 -- Business Continuity & The Coronavirus: Are Your Pharma Operations At Risk?

Expert Advice For All Facets Of Managing Your External CMC Partners

More outsourcing needs to translate to better outsourcing — improved efficiencies, productivity, speed, and CDMO relationships. Easier said than done. But no internal function at a biotech or pharma company can do more to accomplishing these improvements than the CMC group. We’ve collected a series of editorials that feature some frontline examples, and best practices, from a variety of CMC practitioners. Access this free resource.

Featured Editorial
Business Continuity And The Coronavirus: Are Your Pharma Operations At Risk?
By Bikash Chatterjee, chief operating and science officer, Pharmatech Associates

As we face our latest pandemic threat, the need to have a well-defined and tested business continuity management plan in place cannot be overemphasized. Beyond state and national preparedness plans, organizations should be actively evaluating their continuity plans, especially when it comes to strategic contract service providers and partners, to ensure there is a reasonable mitigation plan in place. 

Extension Of The Patient: Expanding The Role Of Caregivers In Biopharma Development
By C. Grace Whiting, National Alliance for Caregiving, and Schiffon L. Wong, EMD Serono

For medical product developers, the role of the caregiver is increasing as innovation advances. Caregivers may provide input on clinical trial concepts, protocol design, informed consent creation, and may also improve clinical trial recruitment and retention.

Industry Insights
Increasing Transparency And Confidence Through Real-Time Data Sharing
Article | By John Chapin and John Morse, Lonza Pharma & Biotech

A digital transformation of biomanufacturing offers a new path for continuous monitoring and optimization of process performance, which would ultimately lead to greater efficiency in drug production.

Providing Solutions At Fair Value: A Spray Drying Case Study
Article | By Frederic Baudry and James Faust, FAREVA

Pharmaceutical companies need CDMO partners that provide solutions at fair value. This CMO has a long history of investing in new technologies with innovators to help their customers achieve their goals, and one recent example is the construction of a new Hastelloy spray-drying unit.

Cost Savings And Speed: The Untapped Value Of A Single-Source Solution
Article | Themo Fisher Scientific

Small and emerging companies face significant challenges in today’s market. This calls for an alternative solution to help them achieve success.

Capitalize On Merger/Acquisition: 4 Tips To Consolidate Your CMO Network
Article | Pfizer CentreOne Contract Manufacturing

Complex CMO networks are expensive and require many resources to manage. Plus, they prevent purchasing and operating at scale. Yet, the process of consolidating CMOs is daunting.

The Criticality Of API CDMO Selection: Insights From A Client
Case Study | Thermo Fisher Scientific

Small and emerging companies face challenges related to limited funding and resources, such as technical expertise and capacity, making it imperative they find a competent partner to support them.

Life Science Leader Magazine

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.